Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India.
PMID: 23735817
2013
Journal of the International AIDS Society
Result: During this time, seven additional participants developed M184V, three developed 69 insertion site mutations and two developed Q151M.
Table: Q151M
Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic.
Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina.
PMID: 24093951
2013
Journal of the International AIDS Society
Method: Sequences were analyzed to identify mutations associated with reduced susceptibility to protease and RT inhibitors, as reported by the International AIDS Society-USA in 2010: RT-M41L, A62V, K65R, D67N, 69 insert, K70R, L74V,V75I, F77L, L100I, K101P, K103N, V106A, V106M, V108I, Y115F, F116Y,
Chemical system biology based molecular interactions to identify inhibitors against Q151M mutant of HIV-1 reverse transcriptase.
Conclusion: In conclusion, our data suggests that the administration of d4T per se is associated with the emergence of both Q151M and K65R MNR mutations which confer resistance to a large range of NRTIs.
Introduction: Q151M confers resistance to all NRTIs, except tenofovir (TDF).
Introduction: Q151M, K65R substitutions, and insertions at codon 69 (Insert69
Introduction: d4T/ddI dual therapy has been associated with the occurrence of Q151M and K65R, as well as young age, low CD4+ T-cell count, high HIV RNA viral load (VL) and experience of more than two ARV regimens before resistance genotyping testing.
Table: Q151M
Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
PMID: 23979732
2013
Antimicrobial agents and chemotherapy
Abstract: In the site-directed mutagenesis studies, a virus containing a K65R substitution exhibited a 0.4-fold change in 50% effective concentration (EC50) versus the wild type, while the majority of viruses with the Q151M constellation (without M184V) exhibited changes in EC50 versus wild type of 0.23- to 0.48-fold.
Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
Method: The Q151M complex of mutations was defined as Q151M alone or in combination with one or more of the following mutations: A62V, V75I, F77L, and F116Y.
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
Discussion: We have previously demonstrated that EFdA is highly efficient in suppressing viral replication of clinical isolates harboring signature mutations to other NRTIs and NNRTIs, including isolates containing 3TC/FTC resistance mutation M184V; TAMs or Q151M complex mutations that confer resistance to AZT, d4T, and abacavir; and nevirapine and efavirenz resistance mutations K103N and Y181C.
Persistence of HIV-1 transmitted drug resistance mutations.
PMID: 23904291
2013
The Journal of infectious diseases
HIV mutation literature information.
PMID: 
2013
Journal of the International AIDS Society
Browser Board
Co-occurred Entities
Filtrator
ViMRT